PVP Ventures Acquires Rs 1.27 Billion Stake in 7Med

29 Aug 2025 CW Team

The transaction, valued at Rs 1.27 billion, involves a mix of primary and secondary stake purchases. This investment aligns with PVP's ambition to build a new-age global healthcare services platform focused on illness, wellness, and care.

Founded by leading nephrology and urology specialists, 7Med operates 22 dialysis centres—both standalone and within hospitals—across six Indian states. It also runs four super-speciality hospitals with a focus on renal care. The company, headquartered in Delhi NCR, employs over 450 professionals and has conducted over one million dialysis procedures to date.

7Med reported an EBITDA of approximately Rs 100 million for FY25, and with PVP’s infusion, aims to scale this to Rs 500 million over the next four years. Expansion plans include broadening its presence in Tier 2 and Tier 3 cities and significantly upgrading local healthcare infrastructure.

Mr Gaurav Davda, Head of M&A and Strategy at PVP, emphasised that the acquisition marks a pivotal step in creating a trusted healthcare brand network tailored to emerging markets. Dr Vijay Kher, Chairman of Epitome Hospitals, added that the partnership would enhance operational efficiency and accelerate access to quality kidney care across geographies.

PVP Ventures, traditionally rooted in real estate, is now actively diversifying through acquisitions. It has partnered with Brigade Enterprises and Casagrand to monetise legacy real estate assets, expecting over Rs 20 billion in cash flows over the next six years, which will be channelled into its healthcare ambitions.

With this deal, PVP Ventures positions itself as a major player in India’s healthcare transformation, targeting both impact and scale in a rapidly growing sector.

PVP Ventures Limited has announced the acquisition of a significant stake in 7Med India Pvt Ltd and Epitome Group of Hospitals, marking a strategic expansion into the healthcare sector. The Board has approved the purchase of an initial 41.2 per cent stake, with a clear roadmap to majority ownership within 12 months and an eventual increase to 76 per cent.The transaction, valued at Rs 1.27 billion, involves a mix of primary and secondary stake purchases. This investment aligns with PVP's ambition to build a new-age global healthcare services platform focused on illness, wellness, and care.Founded by leading nephrology and urology specialists, 7Med operates 22 dialysis centres—both standalone and within hospitals—across six Indian states. It also runs four super-speciality hospitals with a focus on renal care. The company, headquartered in Delhi NCR, employs over 450 professionals and has conducted over one million dialysis procedures to date.7Med reported an EBITDA of approximately Rs 100 million for FY25, and with PVP’s infusion, aims to scale this to Rs 500 million over the next four years. Expansion plans include broadening its presence in Tier 2 and Tier 3 cities and significantly upgrading local healthcare infrastructure.Mr Gaurav Davda, Head of M&A and Strategy at PVP, emphasised that the acquisition marks a pivotal step in creating a trusted healthcare brand network tailored to emerging markets. Dr Vijay Kher, Chairman of Epitome Hospitals, added that the partnership would enhance operational efficiency and accelerate access to quality kidney care across geographies.PVP Ventures, traditionally rooted in real estate, is now actively diversifying through acquisitions. It has partnered with Brigade Enterprises and Casagrand to monetise legacy real estate assets, expecting over Rs 20 billion in cash flows over the next six years, which will be channelled into its healthcare ambitions.With this deal, PVP Ventures positions itself as a major player in India’s healthcare transformation, targeting both impact and scale in a rapidly growing sector.

Infrastructure Urban

04 May 2026

Jyoti Structures FY26 profit rises 56.5%

Jyoti Structures (JSL) recently reported strong financial results for the quarter and year ended 31 March 2026, driven by disciplined execution, cost management and steady progress across its order book.For Q4 FY2025-26, total income rose 44.2 per cent to Rs 2.41 billion from Rs 1.67 billion in Q4 FY2024-25. EBITDA increased 58.6 per cent to Rs 237 million, while EBITDA margin improved by 89 basis points to 9.84 per cent. Profit before tax grew 53.3 per cent to Rs 188.5 million, and net profit rose 51.9 per cent to Rs 181.4 million.For FY2025-26, total income grew 53.1 per cent to Rs 7.72 bill..

Infrastructure Energy

04 May 2026

Cat BEPU to Power Doppstadt Separator at IFAT 2026

Caterpillar’s Cat Battery Electric Power Unit (BEPU) has been selected by Doppstadt to power its SWS 6 Spiral Shaft Separator, which will be showcased for the first time at IFAT 2026 in Munich, Germany, from 4–7 May.The compact plug-and-play BEPU is designed to replace a diesel engine within the same space, using the same mounting locations and relative machine position. It integrates the battery, motor, inverter, onboard charging, cooling and controls, enabling OEMs to electrify existing chassis platforms without extensive redesign.Caterpillar and Cat dealer Zeppelin Power Systems have be..

Infrastructure Urban

04 May 2026

VECV sales rise 6.9% in April 2026

VE Commercial Vehicles, a joint venture between Volvo Group and Eicher Motors, recorded sales of 7,318 units in April 2026, compared to 6,846 units in April 2025, registering 6.9 per cent growth. The total included 7,159 units under the Eicher brand and 159 units under the Volvo brand.Eicher branded trucks and buses reported sales of 7,159 units during the month, up 6.6 per cent from 6,717 units in April 2025. In the domestic commercial vehicle market, Eicher sales rose 8.6 per cent to 6,797 units from 6,257 units a year earlier.Exports declined 21.3 per cent, with VECV recording 362 units in ..